


## L-AP4 monohydrate

<b>Cat. No.:</b>	HY-100781B
<b>CAS No.:</b>	2247534-79-6
<b>Molecular Formula:</b>	C <sub>4</sub> H <sub>12</sub> NO <sub>6</sub> P
<b>Molecular Weight:</b>	201.11
<b>Target:</b>	mGluR
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### BIOLOGICAL ACTIVITY

<b>Description</b>	L-AP4 (L-APB) monohydrate is a potent and specific agonist for the group III mGluRs, with EC <sub>50</sub> s of 0.13, 0.29, 1.0, 249 μM for mGlu <sub>4</sub> , mGlu <sub>8</sub> , mGlu <sub>6</sub> and mGlu <sub>7</sub> receptors, respectively <sup>[1][2]</sup> .											
<b>IC<sub>50</sub> &amp; Target</b>	mGlu <sub>4</sub> 0.13 μM (EC50)	mGlu <sub>8</sub> 0.29 μM (EC50)	mGlu <sub>6</sub> 1.0 μM (EC50)	mGlu <sub>7</sub> 249 μM (EC50)								
<b>In Vivo</b>	<p>L-AP4 (5-30 μg, intrathecal injection 4-5 days) significantly increases the paw withdrawal threshold in response to application of von Frey filaments in eight nerve-ligated rats in a dose-dependent manner. Intrathecal administration of different doses of L-AP4 is not associated with any evident motor dysfunction<sup>[2]</sup>.</p> <p>Intrathecal injection of 30 μg of L-AP4 does not significantly alter the paw withdrawal latency in these normal rats<sup>[2]</sup>.</p> <p>Topical application of 5 to 50 μM L-AP4 to the spinal cord significantly inhibited the evoked response of neurons to touch, pressure, pinch, and von Frey filaments in a concentration-dependent fashion<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Rats.<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>5-30 μg.</td> </tr> <tr> <td>Administration:</td> <td>Intrathecal injection 4-5 days.</td> </tr> <tr> <td>Result:</td> <td>Dose-dependently increased paw withdrawal threshold.</td> </tr> </table>				Animal Model:	Rats. <sup>[2]</sup>	Dosage:	5-30 μg.	Administration:	Intrathecal injection 4-5 days.	Result:	Dose-dependently increased paw withdrawal threshold.
Animal Model:	Rats. <sup>[2]</sup>											
Dosage:	5-30 μg.											
Administration:	Intrathecal injection 4-5 days.											
Result:	Dose-dependently increased paw withdrawal threshold.											

### CUSTOMER VALIDATION

- Biochem Biophys Res Commun. 2020 Dec 17;533(4):1393-1399.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

---

[1]. Selvam C, et al. Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites. J Med Chem. 2018 Mar 8;61(5):1969-1989.

[2]. Chen SR, et al. Distinct roles of group III metabotropic glutamate receptors in control of nociception and dorsal horn neurons in normal and nerve-injured Rats. J Pharmacol Exp Ther. 2005 Jan;312(1):120-6.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA